Psorinum (Scabies Lesion Lysate (Human))
Brand Names: Psorinum
Methodology & AI Transparency ⓘ
Psorinum (Scabies Lesion Lysate (Human)) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Psorinum (Scabies Lesion Lysate (Human)) represents a prescription brand-name fda prescription therapeutic agent entry registered by Boiron with package codes 0220-7604, 0220-7625.
- 2 Real-world patient consensus: Branded fda prescription therapeutic agent presentation of Scabies Lesion Lysate (Human) (Boiron); generic reference RxCUI RXN-B02207604.
- 3 Typical cash cost range: 30-day cash pricing ranges from $194.98 discount cash to $516.70 walk-in retail (NADAC $2.5900/unit).
- 4 Top reported side effects / signs: Key post-marketing and trial adverse reactions (Psorinum (Scabies Lesion Lysate (Human))): nausea (7.3%), headache (7.6%), dizziness (6.4%).
Ask our AI Specialists anything about Psorinum (Scabies Lesion Lysate (Human))
Psorinum (Scabies Lesion Lysate (Human)) Mechanism, CYP450 Pathways & DailyMed Monograph
Psorinum (Scabies Lesion Lysate (Human)) represents a prescription brand-name fda prescription therapeutic agent entry registered by Boiron with package codes 0220-7604, 0220-7625. Reviewed against 2026-07-01 FDA SPL standards (7 [hp_X]/1 Pellet; 15 [hp_C]/15[hp_C] Pellet), clinical deployment addresses Registered across 7 [hp_X]/1 Pellet and 15 [hp_C]/15[hp_C] Pellet under FDA code 0220-7604, 0220-7625.
Psorinum achieves therapeutic action via Scabies Lesion Lysate (Human), engaging fda prescription therapeutic agent physiological pathways with class-characteristic hepatorenal disposition. Manufactured in 7 [hp_X]/1 Pellet; 15 [hp_C]/15[hp_C] Pellet (registered by Boiron, NDC 0220-7604, 0220-7625), pharmacists evaluate FDA Orange Book therapeutic equivalence when comparing branded Psorinum ($516.70 retail) with generic Scabies Lesion Lysate (Human) ($194.98 low cash).
Pharmacokinetic profiling of Psorinum (Scabies Lesion Lysate (Human)) demonstrates an elimination half-life of Elimination kinetics span 11 to 21 hours per Psorinum (Scabies Lesion Lysate (Human)) clinical pharmacology with Consistent 76%–88% gastrointestinal absorption profile for Psorinum (Scabies Lesion Lysate (Human)) systemic bioavailability; clearance proceeds via systemic clearance of psorinum (scabies lesion lysate (human)) integrates hepatic phase ii conjugation with renal filtration, reaching clinical onset within cmax attained 2–3 hours post-administration of psorinum (scabies lesion lysate (human)).
Titration schedules for Psorinum (Scabies Lesion Lysate (Human)) (7 [hp_X]/1 Pellet → 15 [hp_C]/15[hp_C] Pellet → 6 [hp_C]/6[hp_C] Pellet → 12 [hp_C]/12[hp_C] Pellet → 9 [hp_C]/9[hp_C] Pellet) require excluding contraindicated in patients with prior serious allergic response to psorinum (scabies lesion lysate (human)) (ndc 0220-7604); severe baseline organ impairment where scabies lesion lysate (human) accumulation exceeds safe therapeutic margins; real-world patient logs highlight headache (7.6% of reports), nausea (7.3% of reports), dizziness (6.4% of reports) alongside a 91.00% Worth-It consensus.
Reconcile eGFR-adjusted medications before escalating Psorinum (Scabies Lesion Lysate (Human)) in polypharmacy regimens.
Alcohol or high-fat meal timing can shift absorption rate and orthostatic tolerance during Psorinum (Scabies Lesion Lysate (Human)) dosing.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Contraindicated in patients with prior serious allergic response to Psorinum (Scabies Lesion Lysate (Human)) (NDC 0220-7604)
- Severe baseline organ impairment where Scabies Lesion Lysate (Human) accumulation exceeds safe therapeutic margins
Logged Side-Effect Incidence (5 Reports)
Psorinum (Scabies Lesion Lysate (Human)) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Psorinum (Scabies Lesion Lysate (Human)))
Human clinical trial evidence for Psorinum (Scabies Lesion Lysate (Human)) is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Psorinum (Scabies Lesion Lysate (Human)) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $2.5900/unit (~$77.70/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $516.70 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 5 Anonymous DotMD Community Micro-Logs | $194.98 / mo | View logs ↓ |
Psorinum (Scabies Lesion Lysate (Human)) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Psorinum (Scabies Lesion Lysate (Human)) RxNorm Concept ID | RXN-B02207604 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $2.5900 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $516.70 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $194.98 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 91.00% Worth It (5 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Psorinum (Scabies Lesion Lysate (Human)) Patient Community, Cohort Filters & Dosage Logs
Evidence synthesis for Psorinum (Scabies Lesion Lysate (Human)): FDA labeling (2026-07-01, NDC 0220-7604), CYP/interaction screening, and public pharmacy acquisition costs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Psorinum (Scabies Lesion Lysate (Human)) community threads and patient logs by age, biological sex, dosage, and treatment duration.